Literature DB >> 28328134

Somatic PIK3CA mutations in seven patients with PIK3CA-related overgrowth spectrum.

Kit San Yeung1, Janice Jing Kun Ip2, Chin Pang Chow3, Evelyn Yue Ling Kuong4, Paul Kwong-Hang Tam5, Godfrey Chi-Fung Chan1, Brian Hon-Yin Chung1.   

Abstract

Somatic mutations in PIK3CA cause many overgrowth syndromes that have been recently coined the "PIK3CA-Related Overgrowth Spectrum." Here, we present seven molecularly confirmed patients with PIK3CA-Related Overgrowth Spectrum, including patients with Congenital Lipomatous Overgrowth, Vascular Malformations, Epidermal Nevi, Scoliosis/Skeletal and Spinal syndrome, Klippel-Trenaunay syndrome, lymphatic malformation and two with atypical phenotypes that cannot be classified into existing disease categories. The literature on PIK3CA-Related Overgrowth Spectrum, suggests that PIK3CA c.1258T>C; p.(Cys420Arg), c.1624G>A; p.(Glu542Lys), c.1633G>A; p.(Glu545Lys), c.3140A>G; p.(His1047Arg), and c.3140A>T; p.(His1047Leu) can be identified in approximately 90% of patients without brain overgrowth. Therefore, droplet digital polymerase chain reaction targeting these mutation hotspots could be used as the first-tier genetic test on patients with PIK3CA-Related Overgrowth Spectrum who do not have signs of overgrowth in their central nervous system.
© 2017 Wiley Periodicals, Inc. © 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  PIK3CA; PIK3CA-related overgrowth spectrum; somatic mosaicism

Mesh:

Substances:

Year:  2017        PMID: 28328134     DOI: 10.1002/ajmg.a.38105

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  12 in total

1.  Signaling pathways and inhibitors of cells from patients with kaposiform lymphangiomatosis.

Authors:  Elisa Boscolo; Patricia Pastura; Kathryn Glaser; Jillian Goines; Adrienne M Hammill; Denise M Adams; Peter Dickie; Belinda Hsi Dickie; Timothy D Le Cras
Journal:  Pediatr Blood Cancer       Date:  2019-05-02       Impact factor: 3.167

2.  Klippel-Trenaunay Syndrome: Case series from a university hospital of Nepal.

Authors:  Robin Man Karmacharya; Satish Vaidya; Swechha Bhatt; Ashish Tamang; Rohit Bhasink Shrestha; Niroj Bhandari; Bijaya Paudel; Manish Shah; Gaurav Nepal
Journal:  Ann Med Surg (Lond)       Date:  2022-05-07

3.  Clinical Profile of Overgrowth Syndromes Consistent with PROS (PIK3CA-Related Overgrowth Syndromes)-A Case Series.

Authors:  Lydia Mathew; Renu George; Sniya Sudhakar; Shyamkumar N Keshava; N A Fouzia
Journal:  Indian Dermatol Online J       Date:  2020-09-19

4.  Causal somatic mutations in urine DNA from persons with the CLOVES subgroup of the PIK3CA-related overgrowth spectrum.

Authors:  M E Michel; D J Konczyk; K S Yeung; R Murillo; M P Vivero; A M Hall; D Zurakowski; D Adams; A Gupta; A Y Huang; B H Y Chung; M L Warman
Journal:  Clin Genet       Date:  2018-01-25       Impact factor: 4.438

5.  Identification of mutations in the PI3K-AKT-mTOR signalling pathway in patients with macrocephaly and developmental delay and/or autism.

Authors:  Kit San Yeung; Winnie Wan Yee Tso; Janice Jing Kun Ip; Christopher Chun Yu Mak; Gordon Ka Chun Leung; Mandy Ho Yin Tsang; Dingge Ying; Steven Lim Cho Pei; So Lun Lee; Wanling Yang; Brian Hon-Yin Chung
Journal:  Mol Autism       Date:  2017-12-20       Impact factor: 7.509

6.  PIK3CA c.3140A>G mutation in a patient with suspected Proteus Syndrome: a case report.

Authors:  Virginia Valentini; Veronica Zelli; Piera Rizzolo; Valentina Silvestri; Maurizio Alimandi; Maria Michela D'Aloia; Sandra Giustini; Stefano Calvieri; Antonio Giovanni Richetta; Giovanni Monteleone; Laura Ottini
Journal:  Clin Case Rep       Date:  2018-06-02

7.  Upper limb muscle overgrowth with hypoplasia of the index finger: a new over-growth syndrome caused by the somatic PIK3CA mutation c.3140A>G.

Authors:  Mohammad M Al-Qattan; Ali Hadadi; Abdullah M Al-Thunayan; Ahmed A Eldali; Mohammed A AlBalwi
Journal:  BMC Med Genet       Date:  2018-09-04       Impact factor: 2.103

Review 8.  Cancer-Associated PIK3CA Mutations in Overgrowth Disorders.

Authors:  Ralitsa R Madsen; Bart Vanhaesebroeck; Robert K Semple
Journal:  Trends Mol Med       Date:  2018-09-06       Impact factor: 11.951

9.  In vitro efficacy of ARQ 092, an allosteric AKT inhibitor, on primary fibroblast cells derived from patients with PIK3CA-related overgrowth spectrum (PROS).

Authors:  C Ranieri; S Di Tommaso; D C Loconte; V Grossi; P Sanese; R Bagnulo; F C Susca; G Forte; A Peserico; A De Luisi; A Bartuli; A Selicorni; D Melis; M Lerone; A D Praticò; G Abbadessa; Y Yu; B Schwartz; Martino Ruggieri; Cristiano Simone; Nicoletta Resta
Journal:  Neurogenetics       Date:  2018-03-16       Impact factor: 2.660

10.  Clinically and biologically relevant subgroups of Wilms tumour defined by genomic and epigenomic analyses.

Authors:  Jack Brzezinski; Sanaa Choufani; Rodrigo Romao; Cheryl Shuman; Haiying Chen; Joanna Cunanan; Darius Bagli; Ronald Grant; Armando Lorenzo; Rosanna Weksberg
Journal:  Br J Cancer       Date:  2020-10-05       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.